Salud financiera de hoja de balance de Fennec Pharmaceuticals
Salud financiera controles de criterios 0/6
Fennec Pharmaceuticals has a total shareholder equity of $-11.6M and total debt of $30.9M, which brings its debt-to-equity ratio to -266.1%. Its total assets and total liabilities are $26.9M and $38.5M respectively.
Información clave
-266.1%
Ratio deuda-patrimonio
US$30.93m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$13.27m |
| Patrimonio | -US$11.62m |
| Total pasivo | US$38.49m |
| Activos totales | US$26.86m |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
Análisis de la situación financiera
Pasivos a corto plazo: FRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Pasivo a largo plazo: FRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historial y análisis de deuda-patrimonio
Nivel de deuda: FRX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducción de la deuda: FRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: FRX has less than a year of cash runway based on its current free cash flow.
Pronóstico de cash runway: Insufficient data to determine if FRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.